These results suggested that celecoxib might have therapeutic benefits in the particular subgroup of prostate cancers such as obese patients, and that the local expression of COX-2 might not be a biomarker for the response to celecoxib in prostate cancer. Here, PTGS2 is linked to Familial prostate cancer.